DCF — RENOWN SOUTH MEADOWS MED CTR
Enterprise Value: $19.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$19.7M
Enterprise Value
$3.5M
PV of Cash Flows
$16.3M
PV of Terminal Value
$26.2M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $93.8M | $4.2M | 4.0% | $-0.2M | $-0.2M |
| Year 2 | $96.6M | $5.3M | 5.0% | $0.5M | $0.4M |
| Year 3 | $99.5M | $6.4M | 6.0% | $1.2M | $0.9M |
| Year 4 | $102.5M | $7.2M | 7.0% | $1.7M | $1.1M |
| Year 5 | $105.5M | $7.6M | 7.0% | $1.9M | $1.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $19.7M. Terminal value accounts for 82% of total EV — typical range (60-80%).
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$91.0M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.039816542293339086
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5